The strongest genetic risk factor of Behçet's disease (BD) is HLA-B*51. Our group previously reported that HLA-A*26 is independently associated with the risk of the onset of BD apart from HLA-B*51. Here, we re-evaluated the association between HLA-A*26 and BD in the Japanese population. We also performed a comprehensive literature search and meta-analyzed the extracted published data concerning the relationship between HLA-A*26 and BD to estimate the odds ratio (OR) of HLA-A*26 to BD. In this study, we genotyped 611 Japanese BD patients and 2,955 unrelated ethnically matched healthy controls. Genotyping results showed that the phenotype frequency of HLA-A*26 was higher in BD patients than in controls (OR = 2.12, 95% CI: 1.75-2.56). Furthermore, within the HLA-B*51-negative populations, the phenotype frequency of HLA-A*26 was significantly higher in BD patients than in controls (OR = 3.10, 95% CI: 2.43-3.95). Results obtained from meta-analysis combined with our data showed that the modified OR of HLA-A*26 became 1.80 (95% CI:1.58-2.06), whereas within the HLA-B*51-negative population, the modified OR became 4.02 (95% CI: 2.29-7.05). A subgroup analysis arranged by the geographical regions showed HLA-A*26 is in fact associated with the onset of BD in Northeast Asia (OR = 2.11, 95% CI: 1.75-2.56), but not in the Middle East or in Europe.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418292 | PMC |
| http://dx.doi.org/10.1038/s41598-019-40824-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Significant association of HLA-A26 with uveitis and gastrointestinal involvement in patients with Behçet's disease in a multicentre study.
Mod Rheumatol
October 2024
Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Objectives: Specific human leukocyte antigen (HLA) haplotypes are associated with Behçet's disease. Because the effects of HLA-A26 and its combination with HLA-B51 on organ involvement in Behçet's disease have not been well demonstrated, we aimed to examine them.
Methods: This multicentre, cross-sectional, observational study enrolled patients with Behçet's disease who visited Kyoto University Hospital between 2018 and 2021 or Kurashiki Central Hospital between 2006 and 2016 (n = 200).
Resuming anti-TNF therapy after development of miliary tuberculosis in Behcet's disease-related uveitis: a case report.
J Ophthalmic Inflamm Infect
November 2023
Department of Ophthalmology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-Ku, Tokyo, 160-0023, Japan.
Article Synopsis
- There is ongoing debate about restarting anti-tumor necrosis factor (TNF)-α therapy for uveitis after a patient has been treated for active tuberculosis (TB).
- The case involves a 48-year-old Japanese male diagnosed with Behcet disease, who successfully resumed TNF inhibitor treatment after completing therapy for miliary TB.
- The report highlights that with proper treatment of TB and close monitoring, restarting anti-TNF therapy can be a viable option for patients with Behcet disease.
Risk factors, clinical features and treatment of Behçet's disease uveitis.
Prog Retin Eye Res
November 2023
The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China. Electronic address:
Article Synopsis
- Behçet's disease is a type of systemic vasculitis often linked with eye inflammation, specifically uveitis, which tends to be less connected to other organ issues like intestinal or cardiovascular problems.
- Recent studies have revealed different clinical clusters within Behçet's disease, with one theory suggesting that genetics (notably HLA genes) and infections may contribute to its development.
- Current treatment focuses on managing the recurring nature of ocular Behçet's with a mix of corticosteroids and immunomodulatory drugs, and future research aims to better tailor these treatments based on individual patient characteristics.
The Association of Human Leucocyte Antigen (HLA) Class I and II Genes with Cutaneous and Visceral Leishmaniasis in Iranian Patients: A Preliminary Case-Control Study.
Iran J Parasitol
January 2023
Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Background: Leishmaniasis is currently considered a re-emerging or emerging infection based on the geographic region. The outcome of leishmaniasis vastly depends on host interaction. This preliminary study aimed to show the association of human leukocyte antigen (HLA) class I and II genes with healed and non-healed cutaneous leishmaniasis (CL), and symptomatic and asymptomatic visceral leishmaniasis (VL) compared with control groups in Iran.
View Article and Find Full Text PDFComparative Molecular Analysis and Antigenicity Prediction of an Outer Membrane Protein (ompC) of Non-typhoidal Serovars Isolated from Different Food Animals in Lagos, Nigeria.
Bioinform Biol Insights
June 2023
Molecular Biology and Biotechnology Department, Nigerian Institute of Medical Research, Lagos, Nigeria.
Non-typhoidal (NTS) infections occur globally with high morbidity and mortality. The public health challenge caused is exacerbated by increasing rate of antibiotic resistance and absence of NTS vaccine. In this study, we characterized the outer membrane protein C () serovars isolated from different food animals and predicted antigenicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!